PrecivityAD2 is a blood test to aid Alzheimer's diagnosis in adults age 40 and older who already have cognitive symptoms. For younger-onset Alzheimer's families, it offers an earlier, less invasive path to check for amyloid pathology during a clinical workup. Younger-onset Alzheimer's means symptoms start before age 65. It accounts for about 5% of cases and often brings an aggressive course and misdiagnosis, which hits people in their 40s to 60s who are working, parenting, and managing household finances.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Why does the age-40 clearance matter?
- How does the test work?
- How accurate is it?
- What can families do next?
Why does the age-40 clearance matter?
Earlier blood tests left younger adults outside their cleared use. Fujirebio Lumipulse and Roche Elecsys pTau181 were limited to ages 55 and older. PrecivityAD2 is the third FDA-cleared amyloid blood test and the first cleared for patients that young, according to FixFirst Research in its test comparison. C2N Diagnostics announced on Aug.
20, 2026 that regulators cleared PrecivityAD2 for symptomatic adults age 40 and older, as described in the company announcement. That age range reaches more younger-onset families directly. It does not make the test a screening tool for people without symptoms. For families facing job changes, childcare, and financial planning, an earlier answer can shape practical choices. It can also reduce time spent pursuing other explanations for thinking changes.
How does the test work?
PrecivityAD2 uses one blood draw. The laboratory measures amyloid-beta 42/40 plus p-tau217 ratios with high-resolution mass spectrometry. A multi-analyte algorithm score then reports the likelihood of amyloid pathology. Amyloid pathology means abnormal amyloid buildup linked to Alzheimer's disease.
The blood result supports or argues against that pathology as a cause of symptoms. It does not by itself diagnose Alzheimer's disease. A clinician orders the test as part of a broader evaluation. That evaluation still includes history, cognitive checks, medications review, and often other laboratory work. The blood score adds biological evidence to that clinical picture.
How accurate is it?
In a 1,142-person validation study of adults with cognitive signs, PrecivityAD2 showed 97.6% positive predictive value and 93.1% negative predictive value against spinal-fluid tests and brain scans, according to FixFirst Research in its accuracy summary. Positive predictive value means the share of positive blood results confirmed by those reference tests. Negative predictive value means the share of negative blood results confirmed as negative. Those numbers are strong, but they apply to people already having cognitive symptoms.
Results can still disagree with spinal-fluid or PET findings in individual cases. A high score does not prove that amyloid explains every symptom, and a low score does not rule out all other brain conditions. The test also has a defined limit. The Alzheimer's Association states that PrecivityAD2 must be used alongside clinical evaluation in symptomatic people and is not cleared as population screening or a standalone diagnosis, as explained in its clearance statement. Families should expect follow-up testing or referral when results and symptoms do not align.
What can families do next?
Ask for a dementia-focused clinical visit before seeking the test alone. Bring a timeline of thinking, memory, language, behavior, or work-performance changes. Bring a medication list, sleep history, and a family member who has observed daily function.
Use the appointment to decide whether amyloid testing fits now: The blood draw is less invasive than lumbar puncture or amyloid PET as a first step. The FDA-cleared kit was expected to reach U.S. clinicians later in 2026 after laboratory-developed-test availability, so ask the clinic which version it uses and how results will be returned.
- confirm ongoing cognitive symptoms that need an explanation
- review age, history, and other possible causes
- ask whether a blood test, spinal-fluid test, or PET scan fits best
- ask how results would change care, referrals, support, or trial options
- plan who will receive results and what follow-up visit will cover
You Might Also Like
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: A Source-Checked Briefing for Younger-Onset Alzheimer’s Families
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: A Source-Checked Briefing for Younger-Onset Alzheimer’s Families
- The $100 Million PROTECT-Cog Alzheimer’s Study Announced in 2026: How People With Mild Cognitive Impairment Can Avoid Overreading the Headline
